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Abstract 
Background—Although vascular smooth muscle cell (VSMC) proliferation is implicated in 
atherogenesis, VSMCs in advanced plaques and cultured from plaques show evidence of VSMC 
senescence and DNA damage. In particular plaque VSMCs show shortening of telomeres, which 
can directly induce senescence. Senescence can have multiple effects on plaque development and 
morphology; however, the consequences of VSMC senescence or the mechanisms underlying 
VSMC senescence in atherosclerosis are mostly unknown. 
Methods and Results—We examined expression of proteins that protect telomeres in VSMCs 
derived from human plaques and normal vessels. Plaque VSMCs showed reduced expression and 
telomere binding of Telomeric repeat-binding factor-2 (TRF2), associated with increased DNA 
damage. TRF2 expression was regulated by p53-dependent degradation of TRF2 protein. To 
examine the functional consequences of loss of TRF2, we expressed TRF2 or a TRF2 functional 
mutant (T188A) as either gain or loss of function studies in vitro and in ApoE-/- mice. TRF2 
overexpression bypassed senescence, reduced DNA damage, and accelerated DNA repair, 
whereas TRF2188A showed opposite effects. Transgenic mice expressing VSMC-specific 
TRF2T188A showed increased atherosclerosis and necrotic core formation in vivo, whereas 
VSMC-specific TRF2 increased relative fibrous cap and decreased necrotic core areas. TRF2 
protected against atherosclerosis independent of secretion of senescence-associated cytokines. 
Conclusions—We conclude that plaque VSMC senescence in atherosclerosis is associated with 
loss of TRF2. VSMC senescence promotes both atherosclerosis and features of plaque 
vulnerability, identifying prevention of senescence as a potential target for intervention. 
 
Key words: atherosclerosis; vascular disease; smooth muscle; senescence 
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Proliferation of vascular smooth muscle cells (VSMCs) is a central axiom of most models of 
atherosclerosis, promoting atherogenesis as a ‘response to injury’1 or inflammation2. However, 
most heart attacks are caused by rupture of a ‘vulnerable’ plaque with a thin VSMC-poor fibrous 
cap overlying a relatively large necrotic core3,4. Plaque repair requires VSMC proliferation, and 
is thus beneficial at this stage. However, VSMCs from advanced human plaques show poor 
proliferation and premature senescence in culture5 and in vivo6; furthermore, fibrous cap VSMCs 
show extensive DNA damage, marked telomere shortening, and markers of senescence7. 
Although these findings suggest that VSMC senescence may be important in atherogenesis, its 
mechanisms and direct consequences are unproven.  
 Replicative cell senescence is mediated in part by telomeres, which shorten during 
replication and ultimately trigger a DNA damage response (DDR) and growth arrest. Telomeres 
comprise tandem DNA repeats that are maintained in a compact T-loop structure by the shelterin 
complex of telomere-associated proteins, including TRF1, TRF2, POT1, TIN2, RAP1 and TPP1. 
Shelterin proteins restrict access to telomerase and exonucleases/ligases, thus avoiding 
inappropriate telomere elongation and shortening respectively, and prevent exposure of 
chromosome ends that are recognised as double-stranded DNA breaks (DSBs). Although each of 
the shelterin proteins is important for telomere maintenance, Telomeric repeat-binding factor-2 
(TRF2) has a particularly critical role. TRF2 regulates replicative senescence in part by reducing 
telomere length at senescence8,9, and can also stop the ataxia telangiectasia kinase (ATM) from 
initiating a DDR from functional telomeres10. Loss of TRF2 induces multiple features of 
senescence, including irreversible growth arrest, expression of senescence-associated ?-
Galactosidase (SA?G), and telomere dysfunction with chromosomal fusions11-13. TRF2 can also 
regulate cell longevity in a telomere-independent manner by direct association with multiple 
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DDR proteins, including ATM, Nijmegen Breakage Syndrome-1 (NBS1), and Checkpoint 
kinase-2 (Chk2)14-16. ATM phosphorylates TRF2 after DNA damage on T188 in the dimerization 
domain17; defective phosphorylation (e.g. thr > ala, T188A) prevents fast DNA repair following 
DSBs that is only part rescued by the phospho-mimetic glutamic acid (T188E)18. Despite 
differences in mouse and human telomeres, TRF2 inhibition can induce senescence and 
apoptosis in mouse tissues in vivo19. 
We examined the expression of proteins that protect telomeres in human VSMCs derived 
from atherosclerotic plaques or normal arteries. We show that plaque VSMCs show reduced 
expression and telomere binding of TRF2, associated with increased markers of DNA damage. 
Gain and loss of function studies of TRF2 in ApoE-/- mice show that VSMC senescence regulates 
both plaque development and morphology. We conclude that plaque VSMC senescence in 
atherosclerosis is regulated by TRF2, and promotes both atherosclerosis and features of plaque 
vulnerability. 
 
Methods 
Human atherosclerotic plaque and normal vessels 
Plaques and normal aorta were obtained from patients undergoing carotid endarterectomy or 
coronary artery bypass/valve replacement respectively, under informed consent using protocols 
approved by the Cambridge or Huntingdon Research Ethical Committee. Age and sex-matched 
human normal aorta and carotid plaque VSMCs were cultured from tissue explants and studied at 
passages 2–5; VSMC cultures from individual patients were not pooled. Cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal calf serum (FCS) 
supplemented with 100U/ml penicillin, 100?g/ml streptomycin and 2mM L-glutamine. 
 by MARTIN BENNETT on October 16, 2015http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.115.016457 
5 
Protein Extraction, Western blotting 
Protein extraction from cultured cells and Western blotting were performed as previously 
described20 and Supplemental Methods. 
ChIP 
TRF2 association with telomeres was examined by ChIP as described previously21 and 
Supplemental Methods. 
Immunocytochemistry 
Immunocytochemistry for nuclear foci was performed as described previously20 and 
Supplemental Methods. 
Immunohistochemistry 
Immunohistochemistry of human and mouse arteries was performed as described previously22. 
Plasmid Constructs 
cDNAs of human TRF2, TRF2?B (lacking N-terminal basic domain), TRF2?M (lacking C-
terminal Myb domain) and TRF2?B?M (lacking both basic and Myb domains) in retrovirus 
pWZL-hygro-nMyc vectors were purchased from Addgene, Ma, USA (originally supplied by Dr 
Titia de Lange, NY, USA). cDNAs from human TRF2T188A (constitutively un-phosphorylated at 
T188) and TRF2T188E (constitutively phosphorylated) in pTET vector were kind gifts from Dr. 
David Gilley (In, USA) and were subsequently subcloned into the pWZL-hygro-nMyc vector.  
Generation of Stable Cell Lines 
All cDNAs cloned into retrovirus pWZL-hygro-nMyc vectors (TRF2, TRF2?B, TRF2?M, 
TRF2?B?M, TRF2T188A, TRF2T188E) or the empty vector were transfected into Bosc23 ecotropic 
packaging cells using HiPerfect transfection agent (Invitrogen). Replication-deficient virus was 
used to infect mouse ApoE-/- VSMCs. Infected cells were selected with 250μg/ml hygromycin 
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(Roche) and TRF2 expression confirmed by western blot.  
Cell Culture
Mouse cell lines were cultured as described in Supplemental Methods.  
Time Lapse Videomicroscopy 
Cells were cultured overnight in 6-well plates at 3x104 cells/well. Cells were incubated in 40M 
HEPES (pH 7.2) for 1h prior to recording using OpenLab software, taking 3 image frames/well 
using a time-lapse BX51 microscope (Olympus), air-cooled CCD camera (CoolSnap) and 
imaging and analysis software (Soft Imaging Systems). Over 100 cells per cell line were 
analysed and cell proliferation and apoptosis assayed. Non-division was defined as no observed 
divisions over 48 hours (~4 cycles). 
SA?G 
Detection of SA?G was as previously described7. 
Comet Assay 
105 cells were washed in PBS, re-suspended in 150μl 1% low melting point agarose 
(LMPA)/PBS and left to cool on Gelbond plastic films (Lonza) at 4°C for 10 min. After 
immersing in lysis buffer (2.5M NaCl; 100mM EDTA; 10mM Trizma base; pH 10) overnight at 
4°C, gel-films were transferred into electrophoresis buffer (0.3M NaOH; 1mM EDTA; pH>13) 
for 30 min prior to electrophoresis at 24V, 300mA for 30 min at 4°C. Gel-films were washed 3 
times in neutralization buffer (0.4M Tris, pH 7.5), once in distilled H2O and incubated in ice-
cold ethanol for 10 min. Films were dried overnight, rehydrated in distilled H2O for 10 min and 
stained with 2μg/ml EtBr (Sigma) in the dark at room temperature for 2h. Multiple images per 
slide were analysed using a Zeiss microscope and comet tail length/moment measured using 
Comet Assay IV software (Perception Instruments).  
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Experimental Animals 
All animal procedures followed UK Home Office licensing and were approved by the local 
animal ethical committee. To produce constructs for transgenesis, HA tags were inserted at the 
N-terminus of TRF2 and TRF2T188A cDNA by enzymatic reaction. Tagged cDNAs were 
subcloned between the minimal SM22? promoter23 and polyA sequence in a pBS vector. 
Transgenic mice expressing SM22?-TRF2 or -TRF2T188A were generated by pro-nuclear 
injection. Founders were bred to ensure transgene transmission and expression, then backcrossed 
five times with ApoE
-/-
mice prior to experiments. Male and female control ApoE-/-, SM22?-
TRF2/ApoE-/- or SM22?-TRF2T188A/ApoE-/- mice were fed a high fat diet (HFD- 21% total fat, 
0.2% cholesterol, 0% sodium cholate) from 6w-22w, and blood and tissues taken at sacrifice. 
Telomere length and TEL-FISH 
Telomere length and telomere fluorescence in situ hybridisation was undertaken on VSMCs 
derived from control and transgenic mice as described in Supplemental Methods. 
Plaque morphometry 
Atherosclerotic plaque morphometry was determined as described previously24 and in 
Supplemental methods. 
Lipid measurements, blood counts, blood pressure 
Blood was taken from experimental animals every 4 weeks, and serum lipids analysed for total 
cholesterol, triglycerides, LDL and HDL using a Dade-Behring Dimension autoanalyzer and 
LDL calculated using the Friedwald formula. Blood counts were analysed on a Coulter counter, 
and blood pressure determined by tail cuff. 
Cytokine and chemokine detection using FlowCytomix assay 
FlowCytomix assay (eBioscience) was used to determine chemokine (GM-CSF, MCP-1, MCP-3, 
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MIP-1?, MIP-1?, Rantes, CXCL1/KC) and cytokine (IL-6) concentrations in conditioned media 
from cell lines or mouse serum. Samples were analysed according to the manufacturer’s 
recommendations. 
Statistical Analysis 
Data that were normally distributed (e.g. cultured cell foci and mouse plaque sizes) were 
compared using one-way ANOVA (GraphPad Prism, Ca, USA) with no adjustments for multiple 
comparisons. Data that were not normally distributed were examined using Mann Whitney U 
tests. Cumulative data (e.g. cumulative cell proliferation) were examined by comparison of cell 
divisions at the end of the experiment using Mann Whitney U tests. Data are expressed as 
Means±SEM or Means±SD.  p<0.05 was considered statistically significant.  
 
Results 
TRF2 is reduced in human atherosclerotic plaque VSMCs 
As human atherosclerotic plaque VSMCs show shortened telomeres and premature senescence7, 
we first examined expression of shelterin complex proteins in VSMCs cultured from normal 
human aorta or atherosclerotic plaques. Most proteins showed similar expression, but TRF2 was 
reduced in multiple plaque VSMC isolates (Figure 1A). Relative expression of each protein in 
plaque vs. aortic VSMCs was: TRF1 (0.88±0.2, p=0.43), TRF2 (0.76±0.06, p=0.011), POT1 
(0.68±0.3, p=0.06), TIN2 (1.06±0.1, p=0.69), RAP1 (1.03±0.1, p=0.82), TPP1 (0.88±0.13, 
p=0.48)(mean±SD, n=3). In addition, ChIP showed that plaque VSMCs had markedly reduced 
TRF2 bound to telomeres by (Figure 1B), indicating that telomeres in plaque VSMCs are 
unprotected by TRF2.  
TRF2 is regulated at both mRNA and protein levels. There was no difference in TRF2 
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mRNA expression between aortic (n=3) or plaque (n=3) VSMCs (Figure 1C) by qPCR, despite 
the marked differences in TRF2 protein expression, suggesting post transcriptional regulation of 
TRF2 protein. In some cells the stability of TRF2 protein is regulated via ubiquitin-mediated 
proteasomal degradation, itself regulated by a p53-induced E3 ubiquitin ligase siah-1a25. 
Consistent with previous studies26, p53 was increased in whole lysates of human plaques 
compared with normal vessels, and also increased in SMA-positive cells in plaques compared 
with normal aorta (Supplemental Figure 1). p53 itself is also regulated by proteasomal 
degradation, suggesting that this mechanism may be active. Indeed, although p53 protein 
expression was undetectable in plaque and normal human VSMCs by Western blot (not shown), 
expression of siah-1a was increased 1.9-fold in plaque vs. aortic VSMCs, associated with 3.5-
fold increased expression of the senescence marker p16 (n=3) (Figure 1D). To demonstrate 
whether p53 regulated TRF2 expression in VSMCs, we examined TRF2 levels in control or p53-
/- VSMCs after treatment with the proteasomal inhibitor MG132. Proteasomal inhibition 
decreased TRF2 expression in control VSMCs (Figure 1E), associated with increased p53 
expression. TRF2 was increased in p53-/- null VSMCs, consistent with a role for p53 in 
regulating TRF2 protein expression, but there was no significant effect of MG132 (Figure 1E).  
We next examined whether reduced TRF2 expression in plaque VSMCs was associated 
with DNA damage. Cultured plaque VSMCs had reduced TRF2 nuclear foci, associated with 
increased foci of the DNA damage markers phosphorylated ATM (P-ATM) and ?-H2AX 
(Figure 2A-B). Despite reduced TRF2 foci, plaque VSMCs showed increased co-localization of 
TRF2 foci with P-ATM and ?-H2AX, indicating DNA damage at telomeres, and co-localization 
of ?-H2AX with P-ATM (Figure 2A-B). To confirm that TRF2 is also reduced in vivo, and its 
association with DNA damage markers, we examined cells in normal aorta or advanced plaque 
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(AHA Grade IV+). Cells expressing ?-SMA in human plaques in vivo also showed reduced 
TRF2 and increased P-ATM and ?-H2AX expression (Figure 2C-D). These findings suggest 
that TRF2 expression and binding to telomeres is reduced in plaque VSMCs, associated with 
increased DNA damage and DDR activation at telomeres. 
TRF2 bypasses senescence whereas TRF2188A promotes VSMC senescence 
Reduced TRF2 in plaque VSMCs, and the known role of TRF2 in protecting against senescence, 
suggest that TRF2 may be a critical regulator of VSMC senescence. If correct, manipulation of 
TRF2 might be used to increase or decrease senescence in VSMCs in culture and in vivo to study 
the consequences of VSMC senescence on plaque development. TRF2 knockout is embryonally 
lethal in mice27. However, TRF2 contains different functional domains, including a C-terminal 
DNA-binding Myb domain that recognises telomeric tandem repeat sequences at chromosome 
ends, a flexible hinge domain involved in protein–protein interactions, a TRFH domain required 
for homodimerization, and a divergent N-terminal domain rich in basic residues (basic domain). 
Deletion of these regions both alone and together can promote senescence in transformed cells or 
those from newborns, both mouse and human11,12, and thus act as a useful model for loss of 
TRF2 function. However, the effect of loss of TRF2 function varies widely between cell types 
(e.g. 28), and the effect on VSMCs is not known, particularly VSMCs from atherosclerosis 
models such as ApoE-/- mice.  
To find the most effective way of increasing or reducing TRF2 function in VSMCs, we 
stably expressed full-length human TRF2 or truncations lacking the basic domain (?B), the Myb 
domain (?M), or both (?B/?M), or TRF2T188E/A point mutations in mouse Apolipoprotein E-/- 
VSMCs (Supplemental Figure 2A-B). Vector-expressing VSMCs senesced at ~passage 14; 
TRF2, TRF2?B, TRF2?M or TRF2?B?M all promoted cell proliferation (Supplemental Figure 
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2C-D) and cells bypassed senescence until >passage 60. In contrast, TRF2T188A or TRF2T188E 
reduced cell proliferation and cells underwent premature senescence by passage 4, associated 
with increased SA?G expression (Supplemental Figure 2E), indicating that dynamic changes in 
TRF2 phosphorylation are particularly required for function in VSMCs. None of the TRF2 
truncations/mutations significantly increased apoptosis (Supplemental Figure 2D). 
TRF2 promotes DNA repair, whereas TRF2188A delays repair 
We next examined DNA repair after t-BHP, an oxidant that promotes premature senescence in 
VSMCs in part through induction of DSBs and telomere damage7. As TRF2, TRF2?B, TRF2?M 
and TRF2?B?M showed similar effects on cell proliferation and senescence, subsequent studies 
focused on TRF2 and TRF2T188A/E. TRF2 was not detectable in control VSMCs, but t-BHP 
induced transient TRF2 phosphorylation in cells expressing ectopic TRF2, but not TRF2T188A or 
TRF2T188E, again consistent with the known role of this residue in TRF2 phosphorylation 
(Figure 3A). t-BHP increased ?-H2AX expression in control, TRF2T188A and TRF2T188E VSMCs, 
but ?-H2AX expression was markedly reduced in TRF2 VSMCs. ?-H2AX returned to baseline 
by 16h in control and TRF2T188E cells, but TRF2T188A VSMCs maintained ?-H2AX expression to 
16h, indicating long-term unrepaired damage (Figure 3A). Thus, TRF2 inhibits DNA damage 
(as seen by the lack of ?-H2AX expression at baseline and at any stage after DNA damage) and 
TRF2T188A increases damage / inhibits repair (as seen by persistent ?-H2AX at 16h). TRF2 
overexpression also reduced both ?-H2AX and P-ATM foci 1h after t-BHP (Figure 3B-D) and ?-
H2AX foci in recovery (Figure 3E); in contrast, TRF2T188A increased ?-H2AX foci 1h after t-
BHP (Figure 3C), which persisted to >6h in recovery (Figure 3E). TRF2T188E increased early ?-
H2AX induction after t-BHP, but DNA damage normalized by 6h (Figure 3E).  
DSBs can be quantified using an alkaline comet assay, with the kinetics of comet tail 
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shortening reflecting efficiency of DSB repair. t-BHP-induced DSBs were repaired by 6h in 
control VSMCs, but TRF2 accelerated repair with recovery by 2h; TRF-2T188E slowed initial 
DNA repair but was complete by 6h, whilst TRF2T188A VSMCs showed markedly delayed repair 
to >6h (Figure 3F, Supplemental Figure 3). Thus, TRF2 overexpression inhibits replicative 
arrest in VSMCs, accelerates DSB repair after redox stress, and reduces DNA damage. 
TRF2T188A/E induce premature replicative arrest, delay DNA repair and increase DNA damage; 
these effects are most marked with TRF2T188A, and indicate that TRF2 and TRF2T188A can be 
used to examine the effects of prevention or induction of VSMC senescence respectively. 
Generation and characterisation of VSMC-specific TRF2 or TRF2188A transgenic mice 
To determine the role of VSMC senescence in atherogenesis and plaque stability, we generated 
transgenic mice that expressed TRF2 or TRF2T188A from the minimal SM22? promoter 
(Supplemental Figure 4). The minimal SM22 promoter is expressed only in arterial VSMCs in 
adult mice, and not in visceral SMCs, cardiomyocytes or skeletal myocytes23. 3-bp mutations 
were also introduced into the promoter CArG (CC(A/T)6GG-) boxes to prevent promoter down-
regulation when VSMCs undergo phenotypic modulation29. Recent studies have shown that bone 
marrow-derived myeloid cells can express ‘VSMC’ markers in culture and atherosclerosis30, and 
vessel wall-derived VSMCs can also express ‘macrophage’ markers31. However, we have shown 
that this promoter is expressed in <1% of myeloid cells that express ‘VSMC’ markers in 
atherosclerotic plaques in mice30, indicating that expression of transgenes from this promoter are 
specific for vessel-wall derived VSMCs. 
Two founders from each line were studied, which each behaved similarly. SM22?-TRF2 
and SM22?-TRF2T188A mice were born with the expected frequencies, the transgene was 
transmitted between generations, and expressed only in arteries (Figure 4A). Although primary 
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mouse VSMCs proliferate slower than mouse VSMC lines, VSMCs derived from SM22?-TRF2 
mice showed the same features of increased proliferation (Figure 4B), reduced non-dividing % 
(Figure 4C), and accelerated DSB repair (Figure 4D), particularly seen with normalization of 
Comet lengths by 2h (Figure 4D). Similarly, SM22?-TRF2T188A VSMCs showed decreased 
proliferation, increased non-dividing %, and defective initial DSB repair, indicating that 
transgene expression in these mice recapitulates expression of TRF2 and TRF2188A in ApoE-/- 
VSMCs (Supplemental Figure 2). Importantly, apoptosis was similar in all cell types (Figure 
4C), such that functional consequences of transgene expression in vivo were not due to 
increased/decrease VSMC apoptosis. SM22?-TRF2 and SM22?-TRF2T188A mice showed no 
gross vascular or other abnormality, and ?-H2AX expression was similar in aortas of all mouse 
groups, indicating that this overall DNA damage was not affected; in contrast, the senescence 
marker p16 was markedly increased in SM22?-TRF2T188A mice (Figure 4E), confirming that 
TRF2T188A can induce markers of senescence in VSMCs in normal arteries in the absence of 
DNA damage. 
The effect of TRF2 and TRF2T188A on telomeres, telomere length and chromosome 
structure in VSMCs from transgenic mice was examined using qPCR for telomere length and 
telomere fluorescence in situ hybridisation. Although TRF2 reduced telomere length, this was 
not associated with telomere deletions, and there was a trend towards reduced telomere fusions, 
consistent with previous studies indicating a protective role for TRF2 overexpression8,32. In 
contrast, TRF2T188A increased the incidence of telomere deletions, consistent with loss of 
telomere function (Supplemental Figure 5).  
Effects of TRF2 or TRF2188A on atherosclerosis 
To examine the effect of VSMC senescence on atherosclerosis, SM22?-TRF2 and SM22?-
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TRF2T188A mice were backcrossed with C57Bl6/J ApoE-/- mice, and male and female ApoE-/-, 
SM22?-TRF2/ApoE-/-, or SM22?-TRF2T188A/ApoE-/- littermates were fat fed from 6w-22w. 
Body weight, blood pressure, serum lipids, total leukocyte counts, and differential leukocyte % 
showed no differences between groups (Supplemental Figure 6). However, both total 
atherosclerotic plaque and necrotic core areas were significantly increased in aortic root lesions 
of SM22?-TRF2T188A mice (Figures 5 and 6, Table 1). Plaque area was also increased in 
brachiocephalic arteries of SM22?-TRF2T188A mice (0.60±0.08 mm2) and reduced in SM22?-
TRF2/ApoE-/- mice (0.10±0.09 mm2) compared to controls (0.33±0.1 mm2, Mean±SEM 
p=0.047) (Supplemental Figure 7). Similar to human plaques, TRF2 was reduced in VSMCs in 
plaques of ApoE-/- mice vs. the undiseased media (Supplemental Figure 8). 
In humans, rupture-prone plaques exhibit a thin fibrous cap and a relatively large necrotic 
core; we therefore undertook detailed analysis of plaque architecture in these mice. SM22?-
TRF2 mice had significantly increased fibrous cap/plaque and cap/core ratios, and reduced 
core/plaque ratios compared with control ApoE-/- mice (Figure 6A-E, Table 1), indicating a 
relative increase in fibrous cap and decrease in core areas. Overall % SMA-positive, mac3-
positive, and apoptosis frequencies were similar between groups (Table 1), although fibrous caps 
of SM22?-TRF2 mice showed more extensive SMA expression (Figure 5).  
Increased atherosclerosis in SM22?-TRF2T188A mice is not due to a SASP 
Premature senescence may promote atherogenesis by reducing the VSMC content of fibrous 
caps, a major factor in promoting plaque rupture and subsequent growth in humans33. However, 
senescence can also induce a senescence-associated secretome (SASP), a pattern of pro-
inflammatory cytokines released when cells (including VSMCs) undergo replicative or stress-
induced premature senescence34 that might promote atherosclerosis by increasing monocyte 
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invasion. However, both mac3-positive content of plaques (Table 1) and serum levels of SASP 
cytokines were similar (MCP-3, MCP-1, Mip-1?, RANTES) or undetectable (Mip-1?, IL-1, IL-
6) in all mouse groups at 22w (Supplemental Figure 9).  
To determine whether mouse VSMCs expressing TRF2 or TRF2188A showed differences 
in SASP cytokine secretion, we cultured VSMCs expressing these proteins and determined 
cytokine secretion after 2 days. Conditioned media of ApoE-/- VSMCs expressing TRF2 or 
TRF2T188A showed similar cytokine secretion to control cells (Supplemental Figure 10). The 
increased atherosclerosis in SM22?-TRF2T188A mice with a similar SASP profile in vivo and in 
culture thus suggests that VSMCs exert a direct protective effect on the vessel wall. 
Discussion 
VSMC proliferation is a fundamental component of both historical and current models of 
atherogenesis. For example, the ‘response to injury’ hypothesis viewed aberrant VSMC 
proliferation as a major primary event in plaque development. In contrast, more recent models 
suggest that VSMC proliferation is predominantly reparative, for example as a response to 
inflammation35,36. While increased VSMC proliferation is seen in atherogenesis, VSMCs in 
advanced human plaques are characterised by multiple markers of senescence, including 
telomere loss, expression of the cyclin-dependent kinase inhibitors p21 and p16, and expression 
of SA?G7. Although this indicates that VSMC senescence occurs in advanced plaques, it is not 
known whether senescence contributes to plaque development or the morphology of advanced 
lesions, or its underlying mechanisms.  
We demonstrate that human atherosclerotic plaque VSMCs show reduced TRF2 
expression in vitro and markedly reduced binding of TRF2 to telomeres, associated with 
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increased markers of DNA damage. Other shelterin proteins showed no consistently altered 
expression, suggesting that TRF2 is a critical regulator of VSMC senescence in atherosclerosis, 
and that plaque VSMCs are very sensitive to telomere damage. TRF2 was also reduced and 
associated markers of DNA damage increased in ?-SMA-positive cells in human plaques in vivo. 
TRF2 protein was regulated by proteasomal degradation that depended upon p53. TRF2 reduced 
DNA damage, accelerated DSB repair, and inhibited replicative arrest in VSMCs, indicating that 
VSMC senescence may be due to both replicative exhaustion and stress-induced premature 
senescence (SIPS). Using novel gain and loss of function VSMC-specific expression of TRF2 or 
TRF2T188A, we show that VSMC senescence promotes atherosclerosis and features of plaque 
vulnerability, including decreased relative fibrous cap and increased necrotic core areas, without 
a significant SASP. 
We show that TRF2 is unique of the shelterin proteins in being downregulated in plaque 
VSMCs. TRF2 protein is regulated by ubiquitin-mediated degradation, in part by the p53-
induced E3 ubiquitin ligase siah125. VSMCs in plaques are characterised by multiple forms of 
DNA damage, including double and single strand breaks, oxidative lesions and mtDNA 
damage37,38, and DNA damage markers and activation of multiple DNA repair pathways are 
maintained in cultured plaque VSMCs7,20,38. Plaque VSMCs in culture and cells expressing ?-
SMA in human plaques showed down-regulated TRF2 associated with markers of both DNA 
damage (?-H2AX) and DNA repair (p-ATM). In culture, plaque VSMCs showed reduced TRF2 
and increased siah-1a, associated with increased p16. Although overall TRF2 expression was 
reduced after proteasomal inhibition, this was also associated with marked upregulation of p53, 
and the effect of proteasomal inhibition on TRF2 expression was dependent upon p53. This 
suggests a specific mechanism for TRF2 down-regulation in atherosclerosis by which DNA 
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damage-induced activation of p53 and subsequently siah-1a results in TRF2 degradation in 
plaque VSMCs. 
Although studies on human plaque VSMCs do not indicate if reduced TRF2 is a cause or 
consequence of senescence, we show that overexpression of TRF2 from a retrovirus promoter or 
from transgenic mice using the SM22? minimal promoter blocks cell senescence in culture. The 
latter is not a strong promoter, indicating that endogenous levels of TRF2 may be sufficient to 
prevent senescence. This hypothesis is strengthened by our studies using TRF2188A which 
induces senescence in VSMCs that express endogenous levels of wild type TRF2. The use of 
both gain and loss of function studies in vitro that show opposite effects strongly imply that 
TRF2 is a critical regulator of VSMC senescence, and that the observed loss of TRF2 is a major 
factor in VSMC senescence in atherosclerosis. 
To determine the effects of manipulating TRF2 in VSMCs in vivo on atherogenesis and 
plaque morphology directly we generated two novel transgenic mouse models that express 
VSMC-specific TRF2 or TRF2188A as gain or loss of function respectively. TRF2 and TRF2188A 
were expressed at similar levels, a critical control to be able to compare their effects. TRF2 
promoted proliferation, inhibited senescence, and accelerated DNA repair in VSMCs derived 
from SM22?-TRF2 mice, whereas TRF2188A did the opposite. Furthermore, in normal aortas 
TRF2188A increased p16 expression with no change in ?-H2AX, indicating that TRF2188A can 
promote VSMC senescence in the absence of widespread DNA damage. TRF2188A promoted 
plaque development associated with increased plaque and necrotic core areas, whereas TRF2 
expression increased the fibrous cap area relative to both plaque and core areas, and reduced 
relative core size, with no change in apoptosis in either mouse group.  
Recent genetic lineage tracing studies indicate that conventional markers of macrophages 
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can also be expressed by cells derived from the vessel wall31, and markers of VSMCs can also be 
expressed by myeloid cells that differentiate in culture or migrate into the plaque30. This 
potentially might mean that myeloid cells activate ‘VSMC’ promoters when they migrate into 
atherosclerotic plaques, confounding our interpretation that the effects we observe are due to the 
effects of loss of TRF2 on vessel-wall derived VSMCs. However, we and others have shown that 
bone marrow-derived cells expressing SMC markers are either infrequent30 or non-existent39 in 
plaques in ApoE mice, and could not be demonstrated in fibrous caps of advanced plaques at 
22w30. We have also transplanted bone marrow-derived cells into ApoE-/- mice with transgenes 
expressed from the minimal SM22? promoter, which showed that <1% of cells in advanced 
plaques expressed the transgene, and again there was no expression in fibrous caps30. Thus, the 
opposite effects of TRF2 and TRF2188A expression on plaque morphology argue strongly that 
changes in TRF2 function in these transgenic mice are mediated through senescence of vessel 
wall-derived VSMCs. 
Premature senescence may promote atherogenesis by reducing the protective fibrous cap 
(as demonstrated here), or via a senescence-associated secretome (SASP), that might promote 
atherosclerosis by increasing monocyte invasion, or both. However, it has been difficult to 
demonstrate a functionally important SASP in mouse cells, and this often requires culture in 
physiological oxygen concentrations and extreme measures such irradiation40. In addition, 
senescence induced by p16 (which is increased in SM22?-TRF2T188A VSMCs and human plaque 
VSMCs) is often not associated with a SASP41. We find no differences in ‘classical’ SASP 
cytokines in serum of transgenic mice compared with controls, or in cultured VSMCs expressing 
TRF2 of TRF2188A. While it is possible that a local SASP may influence cellular composition 
and morphology of plaques in vivo, other anti-atherogenic effects of VSMCs should also be 
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considered, including acting as a barrier to invasion of monocytes, or prevention of plaque 
rupture that leads to plaque growth. In particular, our findings illustrate the profound protective 
properties of normal VSMC function on the vessel wall, and a novel role of VSMC senescence 
in necrotic core formation. Our results may also explain why accelerated atherosclerosis and 
myocardial infarction are features of progeroid syndromes that show loss of VSMCs, DNA 
damage, and premature cellular senescence42, and why genes that regulate senescence such as the 
INK4/ARF locus might be associated with heart attacks in GWAS studies43.  
Our data support a model of VSMC senescence in atherosclerosis involving telomere 
dysfunction, DNA damage, TRF2 and p53 (Figure 7). In atherogenesis, mitogens from platelets, 
invading myeloid cells, and the local vessel wall promote VSMC replication. Inflammation and 
reactive oxygen species (for example) promote DNA damage, including in telomeres of 
replicating cells. DNA damage also activates p53, resulting in siah1-mediated degradation of 
TRF2, which causes exposure of telomere ends. The combination of replication, loss of TRF2 
protection, and direct DNA damage induce telomere dysfunction. Telomere dysfunction results 
in activation of a DNA damage response that further activates p53, and induction of p16. The 
p53 target p21 and p16 induce senescence, in part mediated through hypophosphorylation of 
pRB. 
In summary, we show that TRF2 is a major regulator of VSMC senescence, and is 
downregulated in VSMCs from human atherosclerotic plaques. VSMC senescence promotes 
atherogenesis and necrotic core formation, while reducing cap formation. Protection against 
VSMC senescence may represent a novel mechanism to reduce both plaque formation and 
features of vulnerable plaques. 
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Table 1. Morphometric and immunohistochemical quantification of aortic root atherosclerotic 
plaques in Control ApoE-/-, SM22?-TRF2/ApoE-/-, and SM22?-TRF2T188A/ApoE-/- mice at 22w 
after fat feeding from 6-22w.  Data are means±SD. *p<0.05 vs. control ApoE-/- mice. 
 Control (ApoE-/-)
(n=18) 
SM22?-
TRF2/ApoE-/- 
(n=11) 
SM22?-
TRF2T188A/ApoE-/-  
(n=11) 
p Value 
(ANOVA)
Plaque area 
(μm2) 
386764 ± 159285 381339 ± 141513 531202 ± 196287* 
 
0.044 
Necrotic core 
area (μm2) 
266685 ± 140666 217660 ± 110186 377240 ± 177253* 0.046 
Cap area (μm2) 123466 ± 43778 163679 ± 60618 159371 ± 43281 0.08 
Cap/Plaque ratio 0.33 ± 0.099 0.45 ± 0.103* 0.33 ± 0.107 0.013 
Cap/Core ratio 0.50 ± 0.211 0.87 ± 0.302* 0.53 ± 0.276 0.003 
Core/Plaque ratio 0.67 ± 0.099 0.55 ± 0.107* 0.67 ± 0.107 0.013 
SMA (% area) 14.17 ± 6.60  14.26 ± 6.27 12.90 ± 5.18 0.85 
Mac3 (% area) 15.94 ± 8.84 14.36 ± 5.98 17.20 ± 6.80 0.70 
TUNEL (% cells) 0.061 ± 0.11 0.209 ± 0.26 0.129 ± 0.195 0.16 
Figure Legends: 
Figure 1. Human Plaque VSMCs show reduced TRF2 expression. (A) Western blot of shelterin 
proteins from normal human aortic (n=3) or plaque VSMCs (n=3). (B) Immunoprecipitation of 
TRF2 with telomere sequences in aorta (Ao) or plaque (Pl) VSMCs (n=3). (C) qPCR for TRF2 
in normal aortic (n=3) or plaque VSMCs. Data are Means±SEM, n=3. (D) Western blot of 
plaque and normal VSMCS for siah1a and p16 (n=3). (E) Western blot of control or p53-/- null 
mouse VSMCs after treatment with 10μM MG132 for 5 hours (n=2).  
 
Figure 2. Human Plaque VSMCs show reduced TRF2 and increased DNA damage. (A) Nuclear 
foci of TRF2, ?-H2AX or P-ATM in aortic or plaque VSMCs. (B) Quantification of single or 
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combined foci (n=20). (C-D) Immunohistochemistry for ?-sm-actin (SMA–blue) and either 
TRF2, ?-H2AX or P-ATM (brown) in normal aorta or plaque. Double-labeled panels are from 
areas indicated in H+E in aortic media and fibrous cap. Scale bars=50μm. Insets are high power 
views of outlined areas. Data are means±SEM, n=5. 
 
Figure 3. TRF2 inhibits and TRF2T188A increases DNA damage. (A) Western blot for TRF2 and 
?-H2AX for ApoE-/- VSMCs expressing vector alone (Cont), TRF2, TRF2T188A, or TRF2T188E, 
after treatment with 100μM t-BHP for 1 hour and recovery (Rec.) for either 2 (upper panels) or 
16 hours (lower panels). (B) Immunocytochemistry of VSMCs from (A) 1h after t-BHP showing 
nuclear foci of TRF2/?-H2AX, or TRF2/P-ATM. (C,D) Quantification of nuclear foci in (B) 1h 
after t-BHP. (E,F) ?-H2AX foci (E) or comet tail moment (F) in VSMCs 1h after t-BHP (time 0) 
and 1,2 or 6 hours recovery. Data are means±SEM. n=3. *p<0.05, **p<0.01 vs. controls. 
 
Figure 4. VSMCs from TRF2 and TRF2T188A transgenic mice show increased or decreased 
proliferation and DNA repair respectively. (A) qPCR for SM22?-TRF2/TRF2T188A transgene 
mRNA in two SM22?-TRF2 or SM22?-TRF2T188A founders (aorta), or gut. (B-D) Basal cell 
proliferation (B) or % cell populations (C), or Comet tail moment after 1h of 100μM t-BHP and 
5h recovery (D) in VSMCs from control or transgenic mice. (E) Western blot for TRF2, ?-H2AX 
and p16 in aortas of control ApoE-/- (Control), SM22?-TRF2/ApoE-/- (TRF2) or SM22?-
TRF2T188A/ApoE-/- (TRF2T188A) at 22w. Data are means±SEM n=3. *p<0.05 vs. controls. 
Figure 5. Effects of TRF2 on plaque development and morphology. Histochemistry and 
immunohistochemistry of control, SM22?-TRF2 or SM22?-TRF2T188A mouse aortic roots for 
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Masson’s Trichrome, ?-SMA and Mac3 at 22w after fat feeding from 6-22w. High power views 
represent areas outlined on corresponding low power views above. Scale bar=500m (low 
power), and 150μm (high power).  
 
Figure 6. Morphometry of plaques in experimental mice. (A-E) Quantification of aortic root 
plaque, core and cap areas and ratios in Control ApoE-/-, SM22?-TRF2/ApoE-/-, and SM22?-
TRF2T188A/ApoE-/- mice at 22w after fat feeding from 6-22w. Data are means±SEM. n=11-18. 
Figure 7. Model of VSMC senescence in atherosclerosis. A full description is given in the text. 
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
Protein Extraction, Western blotting 
Protein extraction from cultured cells and Western blotting were performed as previously 
described1. Tissue was dissected into 25mg pieces with 3 additional freeze-thaw cycles in 
lysis buffer in liquid nitrogen prior to incubation on ice for 12 minutes. Proteins were then 
extracted as per cultured cells. Primary antibodies were used as follows: mouse-TRF1 
(#3529,1:200; Cell Signalling Technology), rabbit-POT1 (ab21382), mouse-TIN2 (ab13791), 
mouse-RAP1 (ab14404) (all 1:5000; Abcam), mouse-TPP1 (B01; Abnova), rabbit-γ-H2AX-
ser139 (#2577), rabbit-TRF2 and mouse-TRF2 (D1Y5D)(#2645 and #13136), rabbit-γ-
Tubulin (#2144), mouse-p53 (#2524; 1C12) (all 1:1000; Cell Signaling Technology) and 
rabbit-p16-INK4A (10883-1-AP, 1:5000; Proteintech). Goat-siah1 (1:1000; ab2237; Abcam), 
HRP-conjugated secondary antibodies were sheep anti-mouse (1:2000; GE Healthcare) and 
donkey anti-rabbit (1:5000; GE Healthcare) in 1% BSA/TBST. 
 
ChIP 
TRF2 association with telomeres was examined by ChIP. In brief, 1-5x106cells were fixed in 
1% formaldehyde for 10 min at room temperature. The reaction was quenched with 125mM 
glycine. Cross-linked cells were scraped, centrifuged and incubated in lysis buffer (1% SDS, 
10mM EDTA pH 8.0, 50mM Tris pH 8.1 and protease inhibitors (Roche)) on ice for 10 min. 
The lysate was then sonicated (Diagenode Bioruptor® Standard) to shear chromatin and 
50µg of chromatin used for immunoprecipitation. Samples were incubated overnight at 4°C 
with either anti-TRF2 (#2645, 1:100, Cell Signalling Technologies) or equivalent isotype 
control (Santa Cruz Biotechnology). Following immunoprecipitation, 40µL of protein A 
dynabeads (Life Technologies) were added to samples and rotated for 1h. Beads/chromatin 
complexes were washed with low salt buffer (2X), high salt buffer (2X), LiCl buffer (1X) and 
TE buffer (2X) and immunocomplexes eluted at 65°C with 10% SDS and 1 mM NaHCO3 
buffer. After addition of 40mM NaCl and formaldehyde, cross-linking was reversed at 65°C 
 overnight. DNA was recovered using a mini-elute DNA purification kit (Qiagen). Telomere 
specific real-time PCR was performed as previously described2. 
 
Immunocytochemistry 
Immunocytochemistry for nuclear foci was performed as described previously1. Primary 
antibodies were rabbit anti-γ-H2AXser139, P-ATM, and TRF2 (#9718, #4526 and #2645, all 
1:100, Cell Signaling Technologies). Secondary antibodies were Alexa Fluro488 goat anti-
mouse IgG and Alexa Fluro694 Goat anti-rabbit IgG (1:500; Invitrogen). γ-H2AXser139 foci 
intensity was assayed using ImageJ (NIH) 
 
Immunohistochemistry 
Immunohistochemistry of human and mouse arteries was performed as described 
previously3. 
 
Cell Culture 
Mouse cell lines were cultured in DMEM supplemented with 10U/ml Penicillin (Sigma), 
10µg/ml Streptomycin (Sigma), 5µg/ml L-Glutamine (Sigma), 10% fetal calf serum (Sigma) ± 
hygromycin. Cells were treated with t-butyl hydroperoxide (t-BHP, 100µM) for 1 hour at 80% 
confluency prior to analysis at selected time points.  
 
Measurement of Telomere Length (Q-PCR) 
The length of mouse telomeres was measured by Q-PCR on a Rotor-Gene (Corbett 
Research) PCR platform. The single-copy control gene (36B4) was measured using forward 
and reverse primers 5’ ACT GGT CTA GGA CCC GAG AAG 3’ and 5’ TCA ATG GTG CCT 
CTG GAG ATT 3’, respectively. The primers used to measure average telomere length were 
5’ CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT 3’ and 5’ GGC TTG 
CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT 3’.  The master mix reaction for 
 36B4 contained 10µl SYBR Green JumpStart Taq ReadyMix (Sigma), 20ng purified DNA in 
5µl, 300nM forward primer, 500nM reverse primer and PCR-grade H2O (Invitrogen) in a 20µl 
final volume. The reaction mix for telomere length was similar to 36B4, except using 300nM 
of both forward and reverse primers. qPCR reaction conditions were 95°C for 15 minutes, 
followed by 35 cycles of elongation steps starting at 95°C for 15 seconds, 54°C for 60 
seconds and 72°C for 30 seconds, and finished at 72°C for 10 minutes. ApoE-/- mouse DNA, 
serially diluted from 60ng to 1.875ng, was used to generate a reaction standard curve. Each 
DNA sample was run in triplicate and two negative controls (no template DNA; no primers) 
were run in duplicate in parallel. The input amounts of telomere and 36B4 DNA were 
calculated based on the standard curve generated after averaging the threshold cycle 
number (Ct) values for each sample. The average telomere length ratio (ATLR) was then 
calculated by dividing the amount of telomeric DNA to the amount of 36B4 product.  
 
Chromosome harvest and and telomere FISH  
To prepare metaphase chromosomes, mouse VSMCs were treated with 0.03µg/mL of 
Colcemid (Gibco, Life Technologies) for 16h, followed a buffered hypotonic solution (0.4% 
KCl in 10 mM HEPES, pH7.4) for 8 min at 37°C. The cells were centrifuged and 
resuspended in 4:1(v/v) methanol:glacial acetic acid and kept at -20°C until use. Metaphase 
preparations were placed onto pre-cleaned microscope slides. Telomere FISH with a Cy3-
TelC PNA probe was performed following the manufacturer’s protocol (PNA Bio inc.). Digital 
images were captured on a Leica DM5000 B microscope equipped with an ORCA-03G CCD 
camera (Hamamatsu) controlled by SmartCapture software (Digital Scientific UK). 
 
Analysis of Atherosclerosis 
Atherosclerosis extent and composition was analyzed as described previously4 Briefly, 
sections from the aortic root and brachiocephalic arteries were stained with H&E, α-SMA, 
 Mac3, and TUNEL. Plaque extent and composition was measured using CellD analysis 
software. The fibrous cap and necrotic core was defined using Masson’s Trichrome. 
 
 
Supplemental Figures!
Supplemental Figure 1 
(A) Western blot for p53 and SMA of whole lysates from normal human aorta (Ao) or 
carotid plaque (Pl). (B) Quantification of Western blots from aortic or plaque lysates. n=4. 
(C) Immunohistochemistry for p53 or SMA in normal human aorta or carotid plaque. Scale 
bars = 150µm. Insets show high power views of areas outlined. (D) Quantification of % of 
VSMCs that express p53 in aortic or plaque sections. n=4. 
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Supplemental Figure 2!
(A) Schematic of TRF2 constructs. Basic, dimerization and myb domains, and nuclear localisation 
signal (NLS) are marked. (B) Western blot for TRF2 in ApoE-/- VSMC lines, including control 
(uninfected) and vector-infected VSMCs. (C) Time-lapse videomicroscopic analysis of % cell 
proliferation over 24 hours in VSMC lines. (D) % cells undergoing cell division, apoptosis or 
senescence in VSMC lines. Data are means±SD. (E).  SAβG expression in VSMC lines at passage 
14 (vector) or passage 4 (TRF2, T188A/E)(Data are means, n=3). *p<0.05, **p<0.01 vs. vector 
lines.!
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Supplemental Figure 3!
Comet assay of VSMCs expressing vector alone, TRF2, TRF2T188A or TRF2188E at 
baseline (Time 0), 1 hr of BHP treatment (BHP) and either 2 or 6 hours after removal of 
BHP (recovery). Scale bar=25µm.!
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Supplemental Figure 4 
Map of transgenic targeting constructs 
Supplemental Figure 5!
(A) Telomere length in mouse ApoE-/- VSMCs (Control), SM22α-TRF2/ApoE-/- VSMCs (TRF2), or SM22α-
TRF2T188A/ApoE-/- VSMCs (TRF2T188A). (B) Telomere FISH of VSMCs derived from ApoE-/ (Control), 
SM22α-TRF2/ApoE-/-) (TRF2) and SM22α-TRF2T188A/ApoE-/- (TRF2T188A) mice. The Telomeric Cy3-
labelled synthetic PNA-(CCCTAA)3 probe is shown in green and chromosomal counterstain (DAPI) in red. 
High magnification examples of end association and telomere deletions are shown on the right. White 
arrows indicate terminal deletion, blue arrows indicate end association. (C) Quantification of % 
chromosomes showing end association or terminal deletion. Scale bar=10µM. Data are means±SD. 
(n=400-1000 chromosomes/genotype).  
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Supplemental Figure 6!
(A-F) Body weight (A), blood pressure (B), serum high density lipoprotein (HDL), low density 
lipoprotein (LDL), Triglycerides (TRI) or total cholesterol (TOT) (C), and leukocyte counts (D-
F), in ApoE-/- (Control), SM22α-TRF2/ApoE-/- (TRF2) and SM22α-TRF2T188A/ApoE-/- 
(TRF2T188A) mice after fat feeding from 6-22w. Data are means±SEM, n=8-12.!
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Supplemental Figure 7!
Brachiocephalic plaques from Control ApoE-/-, SM22α-TRF2/ApoE-/- and , SM22α?TRF2T188A/
ApoE-/- mice after fat feeding from 6-22w. !
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Supplemental Figure 8!
(A) Immunohistochemistry for TRF2 (brown) and SMA (blue) in ApoE-/- mouse plaques or 
undiseased media. High power view of fibrous cap ormedial VSMCs are shown on the right. Scale 
bar=150µm. (B) Quantification of %TRF-2-positive VSMCs in ApoE-/- mouse plaques or undiseased 
media. Data are means±SD (n=8).!
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Supplemental Figure 9!
Serum cytokines from experimental mice at 22w for MCP-3, MCP-1, MIP1β and RANTES after 
fat feeding from 6-22w. Data are means±SEM, n=8-15. !
Supplemental Figure 10!
Cytokines secreted from Control ApoE-/-, TRF2/ApoE-/- and TRF2T188A/ApoE-/- VSMCs. Data are 
means±SEM. n=8-10.!
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